var data={"title":"Penicillin G procaine (intermediate-acting intramuscular): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Penicillin G procaine (intermediate-acting intramuscular): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6745?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=penicillin-g-procaine-intermediate-acting-intramuscular-patient-drug-information\" class=\"drug drug_patient\">see &quot;Penicillin G procaine (intermediate-acting intramuscular): Patient drug information&quot;</a> and <a href=\"topic.htm?path=penicillin-g-procaine-intermediate-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Penicillin G procaine (intermediate-acting intramuscular): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207778\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pfizerpen-AS;</li>\n      <li>Wycillin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207804\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Penicillin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207781\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Inhalational (postexposure prophylaxis):</i> IM: 1,200,000 units every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Not a preferred regimen (Hendricks 2014). Overall treatment duration should be 60 days. Available safety data suggest continued administration of penicillin G procaine for longer than 2 weeks may incur additional risk of adverse reactions. Clinicians may consider switching to effective alternative treatment for completion of therapy beyond 2 weeks (FDA 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cutaneous (treatment):</i> IM: 600,000 to 1,000,000 units daily; <b>Note: </b>Not a preferred regimen (Hendricks 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diphtheria, adjunctive therapy with antitoxin:</b> IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: 300,000 to 600,000 units daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate regimen (patients &gt;10 kg): 600,000 units daily for 14 days (CDC 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diphtheria, carrier state:</b> IM: 300,000 units once daily for 10 days; <b>Note:</b> Penicillin G benzathine is preferred (CDC 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neurosyphilis (including ocular syphilis):</b> IM: 2.4 million units once daily with concomitant probenecid for 10 to 14 days; <b>Note: </b> Aqueous penicillin G IV monotherapy is the preferred initial treatment (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumococcal pneumonia (uncomplicated, moderately severe):</b> IM: 600,000 to 1,000,000 units daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Staphylococcal infections (moderately severe to severe):</b> IM: 600,000 to 1,000,000 units daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Streptococcal infections (Group A; moderately severe to severe):</b> IM: 600,000 to 1,000,000 units daily for a minimum of 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Yaws:</b> IM: 600,000 units daily. <b>Note:</b> Duration dependent upon the stage of disease; azithromycin is the preferred agent (Mitja 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207794\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=penicillin-g-procaine-intermediate-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Penicillin G procaine (intermediate-acting intramuscular): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Anthrax, inhalational (postexposure prophylaxis):</b> Infants, Children, and Adolescents: IM: 25,000 units/kg every 12 hours (maximum: 1,200,000 units/dose every 12 hours). <b>Note:</b> Not a preferred regimen (Bradley 2014). Overall treatment duration should be 60 days. Available safety data suggest continued administration of penicillin G procaine for longer than 2 weeks may incur additional risk for adverse reactions. Clinicians may consider switching to effective alternative treatment for completion of therapy beyond 2 weeks. (FDA 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diphtheria, adjunctive therapy with antitoxin: </b> Infants, Children, and Adolescents: IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: 300,000 to 600,000 units daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\"> Alternate regimen:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients &le;10 kg: 300,000 units daily for 14 days (CDC 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients &gt;10 kg: 600,000 units daily for 14 days (CDC 2014). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diphtheria, carrier state:</b> Infants, Children, and Adolescents: IM: 300,000 units once daily for 10 days; <b>Note:</b> Penicillin G benzathine is preferred (CDC 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syphilis (congenital):</b> Infants and Children: IM: 50,000 units/kg/dose once daily for 10 days; if more than 1 day of therapy is missed, the entire course should be restarted (CDC [Workowski 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207782\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207783\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling, however, excretion is delayed with impaired renal function and dosage adjustments may be necessary. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22154816\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207757\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 600,000 units/mL (1 mL, 2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207741\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207761\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IM: Procaine suspension for deep IM injection only; do not inject in gluteal muscle in children &lt;2 years of age; rotate the injection site; do not administer IV, intravascularly, or intra-arterially since severe and/or permanent neurovascular damage may occur</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207760\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax, prophylaxis:</b> To reduce the incidence of the disease following exposure to aerosolized <i>Bacillus anthracis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anthrax, treatment:</b> Treatment of anthrax, including post-exposure inhalational disease due to aerosolized <i>B. anthracis</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diphtheria:</b> As an adjunct to antitoxin for prevention of the carrier stage of diphtheria caused by susceptible <i>Corynebacterium diphtheriae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, subacute:</b> Treatment of subacute bacterial endocarditis, only in extremely sensitive infections, caused by susceptible group A streptococci.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Erysipeloid:</b> Treatment of erysipeloid caused by susceptible <i>Erysipelothrix rhusiopathiae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fusospirochetosis:</b> Treatment of fusospirochetosis (Vincent gingivitis and pharyngitis) in conjunction with dental care,  and moderately severe infections of the oropharynx caused by susceptible fusiform bacilli and spirochetes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumococcal infection:</b> Treatment of moderately severe infections of the respiratory tract caused by susceptible pneumococci.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with aqueous penicillin G during the acute stage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rat bite fever:</b> Treatment of rat bite fever caused by susceptible <i>Streptobacillus moniliformis</i> and <i>Spirillum minus</i> organisms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue infection:</b> Treatment of moderately severe infections of the skin and soft tissues caused by susceptible staphylococci (penicillin G-susceptible). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Streptococcal infections:</b> Treatment of moderately severe to severe infections of the upper respiratory tract, skin and soft tissue infections, scarlet fever, and erysipelas caused by susceptible streptococci (group A, without bacteremia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Some streptococcal groups, including group D (enterococcus), are resistant. Aqueous penicillin is recommended for streptococcal infections with bacteremia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Syphilis:</b> Treatment of syphilis (all stages) caused by susceptible <i>Treponema pallidum</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Yaws, bejel, and pinta:</b> Treatment of yaws, bejel, and pinta caused by susceptible organisms. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Limitations of use:</i> When high, sustained serum levels are required, use aqueous penicillin G, either intramuscularly (IM) or intravenously (IV). Do not use in the treatment of beta-lactamase-producing organisms, which includes most strains of <i>Neisseria gonorrhea</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207811\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Penicillin may be confused with penicillamine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Penicillin G procaine may be confused with penicillin V potassium </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Wycillin may be confused with Bicillin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207748\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac conduction disturbance, cardiac insufficiency, thrombophlebitis, vasodilatation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Central nervous system stimulation, confusion, drowsiness, myoclonus, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Hemolytic anemia, neutropenia, positive direct Coombs test</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction, hypersensitivity reaction, serum sickness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Jarisch-Herxheimer reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Pain at injection site, sterile abscess at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Interstitial nephritis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207764\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any penicillin or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207745\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactic/hypersensitivity reactions: Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, and/or history of sensitivity to multiple allergens. Use with caution in asthmatic patients. If an allergic reaction occurs, discontinue therapy and institute appropriate supportive measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fibrosis and atrophy:  Quadriceps femoris fibrosis and atrophy have been reported following repeated IM injections of penicillins into the anterolateral thigh.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurovascular damage: Avoid IV, intravascular, or intra-arterial administration since severe and/or permanent neurovascular damage (eg, transverse myelitis with permanent paralysis, gangrene requiring digit or proximal extremity amputation, necrosis and sloughing at and surrounding the injection site) may occur. These reactions have occurred following injection into the deltoid, thigh, or buttock areas. Other serious complications of suspected intravascular administration (eg, immediate distal and proximal pallor, mottling or cyanosis of the extremity around the injection site followed by bleb formation or severe edema requiring anterior and/or posterior compartment fasciotomy in the lower extremity) occur most often in infants and small children. If any evidence of blood supply compromise is noted, consult appropriate specialists promptly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Procaine neuropsychiatric reactions:  Immediate toxic reactions (eg anxiety, confusion, agitation, depression, weakness, seizures, hallucinations, combativeness and expressed &ldquo;fear of impending death&rdquo;) have been reported.  Mental disturbance reactions are more common in patients receiving a large single dose (eg 4.8 million units).  Reactions are transient and last 15 to 30 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Procaine sensitivity:  If there is a history of hypersensitivity to procaine, test with 0.1 mL of 1% or 2% procaine solution.  If erythema, wheal, flare, or eruption occurs, patient may be sensitive to procaine; do not use penicillin G procaine in these patients. Treat sensitivity with supportive measures, including antihistamines.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment; dosage adjustment may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use:  Do not use for the treatment of gonorrhea.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Choice of preparation: Penicillin G procaine is not the same preparation as penicillin G benzathine-penicillin G procaine (eg, <i>Bicillin C-R</i>).  Dispensing errors have occurred (CDC 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Prolonged use: Extended duration of therapy or use associated with high serum concentrations (eg, in renal insufficiency) may be associated with an increased risk for some adverse reactions (neutropenia, hemolytic anemia, serum sickness).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299842\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OAT3</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207750\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9750&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Penicillins. Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OAT3 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207753\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5720603\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Penicillin G crosses the placenta. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects. Penicillin G procaine may be used in the treatment of syphilis during pregnancy (consult current guidelines) (CDC [Workowski 2015]). Penicillin G procaine is also approved for the management of <i>Bacillus anthracis</i>, however other agents are preferred for use in pregnant women (Meaney-Delman 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5706684\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Penicillins are excreted in breast milk. The manufacturer recommends that caution be used when administering penicillin to nursing women. Nondose-related effects could include modification of bowel flora and allergic sensitization.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207755\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity reactions with first dose, injection site reactions, mental status post injection, periodic renal and hematologic function tests with prolonged therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207744\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207763\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Therapeutic: 15 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM: Slow</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: High distribution in kidneys, lesser amounts in liver, skin and intestines. Very small levels found in CSF.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 60%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Within 1 to 4 hours and can persist within the therapeutic range for 15 to 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (60% to 90% as unchanged drug); renal clearance is delayed in neonates, young infants, and patients with impaired renal function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323653\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Penicillin G Procaine Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600000 units/mL (1 mL): $39.84</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F207766\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aquacaine (AU);</li>\n      <li>Benzetacil (MX);</li>\n      <li>Cilicaine Syringe (AU);</li>\n      <li>Hidrociclina (MX);</li>\n      <li>Intrasept (CH);</li>\n      <li>Jenacillin O (DE);</li>\n      <li>Mudapenil (AR);</li>\n      <li>Pam (NL);</li>\n      <li>Penicillinum procainicum (PL);</li>\n      <li>Procain-Penicillin Streuli (CH);</li>\n      <li>Procaine Penicillin. G (FI);</li>\n      <li>Procapen (FI);</li>\n      <li>Retardillin (HU);</li>\n      <li>Servipen-G Forte (CH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Peacock G, Krug SE, Bower WA, Cohn AC, et al. AAP Committee on Infectious Diseases and Disaster Preparedness Advisory Council. Pediatric anthrax clinical management. <i>Pediatrics</i>. doi: 10.1542/peds.2014-0563.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-procaine-intermediate-acting-intramuscular-drug-information/abstract-text/24777226/pubmed\" target=\"_blank\" id=\"24777226\">24777226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), Diphtheria, medical management.  http://www.cdc.gov/diphtheria/clinicians.html. Updated May 2014; Accessed March 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), Inadvertent use of <i>Bicillin C-R</i> to treat syphilis infection &ndash; Los Angeles, California, 1999-2004. <i>MMWR Recomm Rep</i>. 2005;54(09):217-219.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donowitz GR and Mandell GL. Beta-lactam antibiotics. <i>N Engl J Med</i>. 1988;318(7):419-426 and 318(8):490-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-procaine-intermediate-acting-intramuscular-drug-information/abstract-text/3277054/pubmed\" target=\"_blank\" id=\"3277054\">3277054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration (FDA). Prescription drug products: doxycycline and penicillin G procaine administration for inhalational anthrax (post exposure). <i>Federal Register</i>. 2001;66:55,679-55,682.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. <i>Emerg Infect</i>. 2014 Feb. http://dx.doi.org/10.3201/eid2002.130687 Accessed March 24, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. <i>Emerg Infect Dis</i>. 2014;20(2).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-procaine-intermediate-acting-intramuscular-drug-information/abstract-text/24457117/pubmed\" target=\"_blank\" id=\"24457117\">24457117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mitja O, Houinei W, Moses P, et al.  Mass treatment with single-dose azithromycin for yaws. <i>N Engl J Med</i>. 2015;372: 703-710.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paryani SG, Vaughn AJ, Crosby M, et al. Treatment of asymptomatic congenital syphilis: Benzathine versus procaine penicillin G therapy,&rdquo; <i>J Pediatr</i>. 1994; 125(3):471-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-procaine-intermediate-acting-intramuscular-drug-information/abstract-text/8071762/pubmed\" target=\"_blank\" id=\"8071762\">8071762</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Penicillin G Procaine [prescribing information]. New York, NY: Pfizer; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-procaine-intermediate-acting-intramuscular-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wright AJ. The Penicillins. <i>Mayo Clin Proc</i>. 1999;74(3):290-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-procaine-intermediate-acting-intramuscular-drug-information/abstract-text/10090000/pubmed\" target=\"_blank\" id=\"10090000\">10090000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoshikawa TT. Antimicrobial therapy for the elderly patient. <i>J Am Geriatr Soc</i>. 1990; 38(12):1353-1372.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/penicillin-g-procaine-intermediate-acting-intramuscular-drug-information/abstract-text/2254575/pubmed\" target=\"_blank\" id=\"2254575\">2254575</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9750 Version 122.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F207778\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F207804\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F207781\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F207794\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F207782\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F207783\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22154816\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F207757\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F207741\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F207761\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F207760\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F207811\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F207748\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F207764\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F207745\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299842\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F207750\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F207753\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5720603\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5706684\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F207755\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F207744\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F207763\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323653\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F207766\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9750|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=penicillin-g-procaine-intermediate-acting-intramuscular-patient-drug-information\" class=\"drug drug_patient\">Penicillin G procaine (intermediate-acting intramuscular): Patient drug information</a></li><li><a href=\"topic.htm?path=penicillin-g-procaine-intermediate-acting-intramuscular-pediatric-drug-information\" class=\"drug drug_pediatric\">Penicillin G procaine (intermediate-acting intramuscular): Pediatric drug information</a></li></ul></div></div>","javascript":null}